Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

201. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. Full Text available with Trip Pro

Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. Insulin resistance and hyperinsulinemia may play a role in pathogenesis of PCOS. One of the common therapeutic methods is using insulin-sensitizing drugs such as metformin and thiazolidinediones.The purpose was to determine the effect of metformin and pioglitazone on clinical, hormonal and metabolic parameters in women with PCOS.Eighty four women (...) randomly received one of the following for 3 months: metformin (n=28) (500 mg three times a day), pioglitazone (30 mg daily) (n=28) and combination of both metformin and pioglitazone (n=28) (30 mg/day pioglitazone plus 500 mg metformin three times a day). Hormonal profile, fasting serum insulin, body weight, body mass index, menstrual status and waist to hip ratio were evaluated before and after treatment.Metformin and pioglitazone and combination therapy induced favorable changes in fasting serum

2017 International journal of reproductive biomedicine (Yazd, Iran) Controlled trial quality: uncertain

202. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. Full Text available with Trip Pro

Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. Objective To compare the effectiveness of a novel model of care ("Stepping Up") with usual primary care in normalising insulin initiation for type 2 diabetes, leading to improved glycated haemoglobin (HbA1c) levels.Design Cluster randomised controlled trial.Setting Primary care practices in Victoria, Australia, with a practice nurse and at least (...) one consenting eligible patient (HbA1c ≥7.5% with maximal oral treatment).Participants 266 patients with type 2 diabetes and 74 practices (mean cluster size 4 (range 1-8) patients), followed up for 12 months.Intervention The Stepping Up model of care intervention involved theory based change in practice systems and reorientation of the roles of health professionals in the primary care diabetes team. The core components were an enhanced role for the practice nurse in leading insulin initiation

2017 BMJ

203. Both overlapping and independent mechanisms determine how diet and insulin-ligand knockouts extend lifespan of Drosophila melanogaster Full Text available with Trip Pro

Both overlapping and independent mechanisms determine how diet and insulin-ligand knockouts extend lifespan of Drosophila melanogaster Lifespan in many organisms, including Drosophila melanogaster, can be increased by reduced insulin-IGF-like signaling (IIS) or by changes in diet. Most studies testing whether IIS is involved in diet-mediated lifespan extension employ only a few diets, but recent data shows that a broad range of nutritional environments is required. Here, we present lifespan (...) data of long-lived Drosophila, lacking three of the eight insulin-like peptides [Drosophila insulin-like peptides 2,3,5 (dilp2-3,5)] on nine different diets that surround the optimum for lifespan. Their nutritional content was varied by manipulating sugar and yeast concentrations independently, and thus incorporated changes in both diet restriction and nutrient balance. The mutants were substantially longer-lived than controls on every diet, but the effects on the lifespan response to sugar

2017 NPJ aging and mechanisms of disease

204. Different insulin types and regimens for pregnant women with pre-existing diabetes. Full Text available with Trip Pro

Different insulin types and regimens for pregnant women with pre-existing diabetes. Insulin requirements may change during pregnancy, and the optimal treatment for pre-existing diabetes is unclear. There are several insulin regimens (e.g. via syringe, pen) and types of insulin (e.g. fast-acting insulin, human insulin).To assess the effects of different insulin types and different insulin regimens in pregnant women with pre-existing type 1 or type 2 diabetes.We searched the Cochrane Pregnancy (...) and Childbirth Group's Trials Register (30 October 2016), ClinicalTrials.gov (17 October 2016), the WHO International Clinical Trials Registry Platform (ICTRP; 17 October 2016), and the reference lists of retrieved studies.We included randomised controlled trials (RCTs) that compared different insulin types and regimens in pregnant women with pre-existing diabetes.We had planned to include cluster-RCTs, but none were identified. We excluded quasi-randomised controlled trials and cross-over trials. We

2017 Cochrane

205. Insulin aspart (Fiasp) - Diabetes Mellitus

Insulin aspart (Fiasp) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 10 November 2016 EMA/CHMP/50360/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Fiasp International non-proprietary name: insulin aspart Procedure No. EMEA/H/C/004046/0000 Note Assessment report as adopted (...) by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/50360/2017 Page 2/132 Administrative information Name of the medicinal product: Fiasp Applicant: Novo Nordisk A/S Novo Alle 2880 Bagsvaerd DENMARK Active substance: INSULIN ASPART International Non-proprietary Name/Common Name: insulin aspart Pharmaco-therapeutic group (ATC Code): insulins and analogues, insulins and analogues for injection, fast-acting (A10AB05) Therapeutic indication(s): Treatment

2017 European Medicines Agency - EPARs

206. [Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin]

[Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin] Évaluation des retombées de la mise en oeuvre du guide d'usage optimal sur l'autosurveillance glycémique chez les adultes atteints de diabète de type 2 non traités par l'insuline [Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin (...) ] Évaluation des retombées de la mise en oeuvre du guide d'usage optimal sur l'autosurveillance glycémique chez les adultes atteints de diabète de type 2 non traités par l'insuline [Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin] Lobè C, Tremblay E, Premont A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2017 Health Technology Assessment (HTA) Database.

207. Safer insulin prescribing

Safer insulin prescribing Safer insulin prescribing Safer insulin prescribing Key therapeutic topic Published: 16 January 2017 nice.org.uk/guidance/ktt20 pathways K Ke ey points y points Several new insulin products have been launched in recent years, including high-strength, fixed-combination and biosimilar insulins. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice for healthcare professionals to minimise the risk of medication error with these products (...) . Hypoglycaemia is an inevitable adverse effect of insulin therapy. All the NICE guidelines on diabetes recommend that people receiving insulin therapy are provided with education and information about awareness and management of hypoglycaemia. Diabetes features in the NHS Long T erm Plan published in January 2019. Options for local implementation: Options for local implementation: Be aware of the differences between insulin products and ensure that people receive appropriate training on their correct use

2017 National Institute for Health and Clinical Excellence - Advice

208. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. (Abstract)

Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. Previous clinical trials showing the benefit of continuous glucose monitoring (CGM) in the management of type 1 diabetes predominantly have included adults using insulin pumps, even though the majority of adults with type 1 diabetes administer insulin by injection.To determine the effectiveness of CGM in adults with type 1 diabetes treated (...) with insulin injections.Randomized clinical trial conducted between October 2014 and May 2016 at 24 endocrinology practices in the United States that included 158 adults with type 1 diabetes who were using multiple daily insulin injections and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%.Random assignment 2:1 to CGM (n = 105) or usual care (control group; n = 53).Primary outcome measure was the difference in change in central-laboratory-measured HbA1c level from baseline to 24 weeks. There were 18

2017 JAMA Controlled trial quality: predicted high

209. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. (Abstract)

Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. The majority of individuals with type 1 diabetes do not meet recommended glycemic targets.To evaluate the effects of continuous glucose monitoring in adults with type 1 diabetes treated with multiple daily insulin injections.Open-label crossover randomized clinical trial conducted in 15 diabetes outpatient (...) clinics in Sweden between February 24, 2014, and June 1, 2016 that included 161 individuals with type 1 diabetes and hemoglobin A1c (HbA1c) of at least 7.5% (58 mmol/mol) treated with multiple daily insulin injections.Participants were randomized to receive treatment using a continuous glucose monitoring system or conventional treatment for 26 weeks, separated by a washout period of 17 weeks.Difference in HbA1c between weeks 26 and 69 for the 2 treatments. Adverse events including severe hypoglycemia

2017 JAMA Controlled trial quality: predicted high

210. Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases Full Text available with Trip Pro

Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases Protein aggregation is a pathological hallmark of and may play a central role in the neurotoxicity in age-associated neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Accordingly, inhibiting aggregation of amyloidogenic proteins, including amyloid β and α-synuclein, has been a main therapeutic target for these disorders. Among (...) neurodegenerative diseases may lead to increasing efficacy. Meanwhile, type II diabetes mellitus has been associated with an increased risk of neurodegenerative disease, such as Alzheimer's disease and Parkinson's disease, and studies have shown that metabolic dysfunction and abnormalities surrounding insulin signaling may underlie disease progression. Naturally, "anti-insulin resistance" therapy has emerged as a novel paradigm in the therapy of neurodegenerative diseases. Indeed, incretin agonists, which

2017 NPJ Parkinson's disease

211. Basal-Bolus Versus Sliding-Scale Insulin Therapy in the Acute Care Hospital Setting: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness

Basal-Bolus Versus Sliding-Scale Insulin Therapy in the Acute Care Hospital Setting: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness Basal-Bolus Versus Sliding-Scale Insulin Therapy in the Acute Care Hospital Setting: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Basal-Bolus Versus Sliding-Scale Insulin Therapy in the Acute Care Hospital Setting: A Review of Comparative Clinical Effectiveness and Cost (...) -Effectiveness Basal-Bolus Versus Sliding-Scale Insulin Therapy in the Acute Care Hospital Setting: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness Published on: January 12, 2017 Project Number: RC0840-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of basal-bolus versus sliding-scale insulin therapy for adult patients with type 1 and type 2 diabetes in the acute care hospital

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

212. Breastfeeding an Infant or Young Child with Insulin-Dependent Diabetes

Breastfeeding an Infant or Young Child with Insulin-Dependent Diabetes ABM Protocol ABM Clinical Protocol #27: Breastfeeding an Infant or Young Child with Insulin-Dependent Diabetes Diana Miller, 1,2 Leena Mamilly, 1 Shannon Fourtner, 1 Casey Rosen-Carole, 3 and the Academy of Breastfeeding Medicine A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols for managing (...) commonmedicalproblemsthatmayimpactbreastfeedingsuccess.Theseprotocolsserveonlyasguidelinesforthe careofbreastfeedingmothersandinfantsanddonotdelineateanexclusivecourseoftreatmentorserveasstandards ofmedicalcare.Variationsintreatmentmaybeappropriateaccordingtotheneedsofanindividualpatient. Purpose T o provide guidance for the care of breastfeeding in- fants or young children with insulin-dependent diabetes mellitus (called diabetes in this protocol) and their families, describing: 1. The basis of insulin dosing for carbohydrate intake for breastfeeding infants 2. The basis of assessing

2017 Academy of Breastfeeding Medicine

213. LEVEMIR (insulin detemir), long-acting human insulin analogue

LEVEMIR (insulin detemir), long-acting human insulin analogue Haute Autorité de Santé - LEVEMIR (insuline détémir), analogue de l’insuline humaine d’action lente Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments LEVEMIR (insuline détémir), analogue de l’insuline humaine d’action lente Substance active (DCI) insuline détémir DIABETOLOGIE (...) - Nouvelle indication Nature de la demande Extension d'indication Avis de la CT du 21 septembre 2016 Pas d’avantage clinique démontré par rapport à TRESIBA dans la prise en charge du diabète de type 1 de l’enfant âgé de 1 an à 2 ans LEVEMIR a désormais l’AMM dans le diabète de type 1 chez l’enfant dès l’âge de 1 an. Les données cliniques d’efficacité disponibles chez l’enfant entre 1 et 2 ans, sont limitées à une étude de non infériorité versus insuline dégludec portant sur un effectif de 350 enfants

2017 Haute Autorite de sante

216. Xultophy (insulin degludec and liraglutide) - type 2 diabetes

Xultophy (insulin degludec and liraglutide) - type 2 diabetes Xultophy® (insulin degludec and liraglutide) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Xultophy® (insulin degludec and liraglutide) Conclusion Xultophy® (insulin degludec and liraglutide) is a combination product for treatment of type 2 diabetes administered by one daily injection consisting of insulin degludec and the GLP-1 receptor agonist (GLP1-RA) liraglutide. The dose (...) is administered by a pre-filled injection pen with a fixed-ratio combination of insulin degludec and liraglutide, which offers a less flexible dose adjustment. The maximum daily dose is 50 dose steps corresponding to 50 units insulin degludec/1.8 mg liraglutide. In clinical studies, Xultophy has been demonstrated to reduce HbA1c more than both insulin degludec, liraglutide and insulin glargin in combination with existing treatment with different oral antidiabetics. Compared to the above-mentioned insulins

2017 Danish Pharmacotherapy Reviews

217. Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus

Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus Search > > Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus - Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus Published on 16 October 2017 Guidance Recommendation (...) The Ministry of Health's Drug Advisory Committee has recommended: Insulin glargine biosimilar (Basaglar) injection 100 units/ml cartridge for the treatment of type 1 and type 2 diabetes mellitus in adults, adolescents and children aged 6 years or above, where treatment with insulin is required. Subsidy status Insulin glargine biosimilar (Basaglar) injection 100 units/ml cartridge is recommended for inclusion on the Standard Drug List (SDL) for the abovementioned indication. The manufacturer has offered

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

218. Initiating basal insulin in type 2 diabetes mellitus

Initiating basal insulin in type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Initiating basal insulin in type 2 diabetes mellitus Search > > Initiating basal insulin in type 2 diabetes mellitus - Initiating basal insulin in type 2 diabetes mellitus Published on 20 November 2017 This Appropriate Care Guide (ACG) continues from the ACG on oral glucose-lowering agents in type 2 diabetes mellitus (T2DM) and highlights the importance of not delaying insulin therapy. It provides (...) clinicians with a practical guide on initiating basal insulin in T2DM and how to prevent and manage hypoglycaemia. Download the PDF below to access the full ACG. Key Messages 1. Start insulin therapy if glycaemic goals are not met on oral glucose-lowering agents alone. 2. Initiate with basal insulin, such as intermediate- or long-acting insulin. 3. When initiating insulin, review concomitant oral glucose-lowering agents. Continue metformin +/- SGLT-2 inhibitors where appropriate. 4. Educate patients

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

219. Insulin glargine (Lusduna) - Diabetes Mellitus

Insulin glargine (Lusduna) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 10 November 2016 EMA/813309/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report LUSDUNA International non (...) -proprietary name: insulin glargine Procedure No. EMEA/H/C/004101/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised Assessment report EMA/813309/2016 Page 2/76 Table of contents 1. Background information on the procedure 10 1.1. Submission of the dossier 10 1.2. Steps taken for the assessment of the product 10 2. Scientific discussion 11 2.1. Introduction 11 2.2. Quality aspects 12 2.2.1

2017 European Medicines Agency - EPARs

220. Insulin Degludec (Tresiba, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Insulin Degludec (Tresiba, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks ©Institute for Clinical and Economic Review, 2016 Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Report March 14, 2016 Institute for Clinical and Economic Review ©Institute for Clinical and Economic Review, 2016 Page i Final Report – Insulin Degludec AUTHORS: Jeffrey A. Tice (...) Review DATE OF PUBLICATION: March 14, 2016 We would also like to thank Shanshan Liu, Elizabeth Russo, Matt Seidner, Patricia Synnott, and Karin Travers of ICER for their contributions to this report. ©Institute for Clinical and Economic Review, 2016 Page ii Final Report – Insulin Degludec About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders

2017 California Technology Assessment Forum